Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,746,347
  • Shares Outstanding, K 63,928
  • Annual Sales, $ 0 K
  • Annual Income, $ -152,150 K
  • EBIT $ -270 M
  • EBITDA $ -278 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.06

Options Overview Details

View History
  • Implied Volatility 100.53% (-1.22%)
  • Historical Volatility 51.92%
  • IV Percentile 66%
  • IV Rank 31.03%
  • IV High 228.19% on 05/30/25
  • IV Low 43.10% on 08/21/25
  • Expected Move (DTE 8) 4.83 (11.43%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 718
  • Volume Avg (30-Day) 701
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 19,677
  • Open Int (30-Day) 17,973
  • Expected Range 37.41 to 47.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.34
  • Number of Estimates 7
  • High Estimate -1.12
  • Low Estimate -1.62
  • Prior Year -0.72
  • Growth Rate Est. (year over year) -86.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.87 +3.35%
on 02/05/26
49.75 -15.10%
on 01/14/26
-4.22 (-9.08%)
since 01/12/26
3-Month
27.19 +55.35%
on 11/21/25
56.05 -24.64%
on 12/24/25
+11.16 (+35.91%)
since 11/12/25
52-Week
18.53 +127.95%
on 04/09/25
56.05 -24.64%
on 12/24/25
+7.69 (+22.26%)
since 02/12/25

Most Recent Stories

More News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 42.24 (-1.68%)
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 42.24 (-1.68%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 42.24 (-1.68%)
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 42.24 (-1.68%)
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy...

VERA : 42.24 (-1.68%)
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 42.24 (-1.68%)
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative...

VERA : 42.24 (-1.68%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics...

VERA : 42.24 (-1.68%)
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 42.24 (-1.68%)
Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

VERA : 42.24 (-1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 45.36
2nd Resistance Point 44.43
1st Resistance Point 43.33
Last Price 42.24
1st Support Level 41.30
2nd Support Level 40.37
3rd Support Level 39.27

See More

52-Week High 56.05
Last Price 42.24
Fibonacci 61.8% 41.72
Fibonacci 50% 37.29
Fibonacci 38.2% 32.86
52-Week Low 18.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar